BMRN BioMarin Pharmaceutical Inc.

88.00
+0.67  (1%)
Previous Close 87.33
Open 87.65
Price To book 5.47
Market Cap 15.36B
Shares 174,490,000
Volume 933,838
Short Ratio 6.44
Av. Daily Volume 1,122,590

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 update due at International Society of Thrombosis and Haemostasis (ISTH) 2017 Congress, July 8-13, 2017. Phase 2b trial to be initiated 3Q 2017.
BMN 270
Hemophilia A
Phase 3 trial initiation announced December 12, 2016.
Vosoritide
Achondroplasia
Phase 3 data released March 2016. Primary endpoint hit. Key secondary endpoint missed. BLA filing to be filed 2Q 2017.
Pegvaliase
Phenylketonuria (PKU)
Program terminated June 2016
Reveglucosidase alfa (BMN 701)
Pompe Disease
Approved February 14, 2014.
Vimizim (GALNS)
(MPS IVA) Morquio A Syndrome
PDUFA date extended by three months to April 27 2017. Approval announced April 27, 2017.
Cerliponase alfa
Batten Disease
CRL issued January 14, 2016.
Kyndrisa
Duchenne Muscular Dystrophy (DMD)

Latest News

  1. Ultragenyx Receives Priority Review for rhGUS from FDA
  2. Why Sangamo Therapeutics Inc. Jumped Higher Today
  3. Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death
  4. BioMarin Pharmaceutical Inc. Moves Toward Profitability
  5. Edited Transcript of BMRN earnings conference call or presentation 4-May-17 8:30pm GMT
  6. BioMarin Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : BMRN-US : May 9, 2017
  7. BioMarin: Is Profitability On The Horizon?
  8. These Biotechs Are Grabbing Bullish Views In Wake Of Earnings
  9. BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up
  10. BioMarin reports 1Q loss
  11. BioMarin Announces First Quarter 2017 Financial Results
  12. Investor Network: BioMarin Pharmaceutical Inc. to Host Earnings Call
  13. [$$] Did Gilead Cut Buybacks for Acquisition?
  14. Why Earnings Season Could Be Great for BioMarin (BMRN)
  15. BioMarin to Attend Two Upcoming Investor Conferences
  16. BioMarin CEO says 'the system will have to determine' the...
  17. BioMarin CEO says 'the system will have to determine' the worth of its new $702,000 drug
  18. Today's Research Reports on Biotech Stocks to Watch: Pacific Biosciences of California and BioMarin Pharmaceutical
  19. BioMarin wins FDA approval for life-changing drug for kids — with a $700,000-per-year cost
  20. BioMarin Prices Orphan Drug at $702,000, Promises Big Discounts